Duquesne Family Office - JUNO THERAPEUTICS INC ownership

JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 166 filers reported holding JUNO THERAPEUTICS INC in Q4 2016. The put-call ratio across all filers is 1.25 and the average weighting 1.0%.

Quarter-by-quarter ownership
Duquesne Family Office ownership history of JUNO THERAPEUTICS INC
ValueSharesWeighting
Q3 2016$14,795,000
+304.8%
493,000
+604.3%
1.31%
+265.4%
Q4 2014$3,655,00070,0000.36%
Other shareholders
JUNO THERAPEUTICS INC shareholders Q4 2016
NameSharesValueWeighting ↓
Biomark Capital Management Co. LLC 2,168,601$40,878,00084.62%
Crestline Management, LP 17,348,799$327,025,00081.61%
Omega Fund Management, LLC 1,229,512$23,176,00018.81%
SIB LLC 100,000$1,885,0001.52%
BB BIOTECH AG 1,870,000$35,250,0001.31%
Clearline Capital LP 116,200$2,190,0000.99%
ARK Investment Management 141,976$2,676,0000.97%
Clarius Group, LLC 117,896$2,222,0000.94%
SCOPIA CAPITAL MANAGEMENT LP 1,778,724$33,529,0000.64%
Baillie Gifford 11,061,955$208,518,0000.34%
View complete list of JUNO THERAPEUTICS INC shareholders